Manelimab

玛奈利单抗

Report date: 2022/07/19 20:00:45

Base Information

Drug NameManelimab
Drug Alias NameAnti PD-L1 mAbBCD-135
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBIOCAD JSC
Active IndicationsN/A
Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A